Wave (WVE) Q4 revenue USD 17.2 million (-79.4%)

Reuters02-26
Wave (WVE) Q4 revenue USD 17.2 million (-79.4%)

Wave Life Sciences reported Q4 2025 revenue of USD 17.2 million (-79.4%) and a net loss of USD 53.2 million, with R&D expenses of USD 52.8 million (+18.3%) and G&A expenses of USD 20.9 million (+29.5%). For FY 2025, revenue was USD 42.7 million (-60.6%) and net loss was USD 204.4 million, with R&D expenses of USD 182.8 million (+14.5%) and G&A expenses of USD 75.3 million (+27.6%). Cash and cash equivalents totaled USD 602.1 million as of Dec. 31, 2025, and Wave Life Sciences said it expects its cash runway into Q3 2028. On the pipeline, Wave Life Sciences reiterated plans for an INLIGHT clinical data update in Q1 2026 for WVE-007 in obesity (including 6-month follow-up from the 240 mg cohort and 3-month follow-up from the 400 mg cohort) after interim data showed fat loss similar to GLP-1 at three months with muscle preservation and sustained suppression of serum Activin E supporting once- or twice-yearly dosing. The company is planning to initiate the Phase 2a multidose portion of INLIGHT in H1 2026 and expects to start additional WVE-007 trials as an incretin add-on and as post-incretin maintenance in 2026. For WVE-006 in alpha-1 antitrypsin deficiency, Wave Life Sciences said the RestorAATion-2 trial is fully enrolled through the 600 mg cohort, with 400 mg multidose data expected in Q1 2026 and regulatory feedback on a potential accelerated approval pathway anticipated mid-2026. Wave Life Sciences also said a CTA submission for WVE-008 in PNPLA3 I148M liver disease remains on track for 2026, and it remains on track to file an NDA in 2026 to support accelerated approval of WVE-N531 for DMD (exon 53).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260730PRIMZONEFULLFEED9661770) on February 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment